CMV vaccines

US11554169B2 · kind B2 · utility

Assignee

• Hookipa Biotech GmbH · AT

Inventors

• Klaus Orlinger · Wien, AT
• Karen Lingnau · Wien, AT
• Thomas P. Monath · Harvard, US
• Farshad Guirakhoo · Atlanta, US
• Gerhard Fuhrmann · Wien, AT
• Katherine Cohen · Wien, AT
• Vera Baumgartl-Strasser · Purkersdorf, AT
• Andreas Aspöck · Wien, AT
• Manuela Kainer · Neulengbach, AT
• Bernhard Brim · Mauerbach, AT
• Bettina Kiefmann · Wien, AT
• Elizabeth Watson · Wien, AT
• Mario Aistleithner · Wien, AT
• Katharina Bayer · Mistelbach, AT
• Elsa Mühlbacher · Wien, AT

Key dates

• Filing date: Sep 20, 2018
• Grant date: Jan 17, 2023
• Expiry date: Sep 20, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.